Compare AbCellera Biologics Inc (ABCL) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Xpeng Inc - ADR — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Xpeng Inc - ADR trades at $13.19 (market cap $12.75B). The key difference: Xpeng Inc - ADR is far larger — about 5.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ABCL | XPEV | |
|---|---|---|
Market Cap | $2.35B | $12.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $28.07 |
52-Week Low | $2.78 | $12.09 |
Enterprise Value | $1.99B | $14.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
XPeng (XPEV) trades at $13.17, up 0.69% today, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with negative profitability ratios. Recent news highlights vehicle delivery growth and advancements in autonomous driving technology, but the stock faces headwinds from broader EV sector challenges.
The outlook remains cautious due to persistent losses and competitive pressures, though analyst consensus is bullish with 64.7% buy ratings. Key risks include execution on profitability, intense EV competition, and regulatory uncertainties. Revenue expansion and technology innovation present opportunities if the company can achieve sustained margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
